Results 11 to 20 of about 6,725 (159)

Anti-tumour and radiosensitising effects of PARP inhibitor on cervical cancer xenografts

Journal of Obstetrics and Gynaecology, 2023
This study evaluated the radiosensitising effect of niraparib; a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor on HeLa cervical cancer cells in nude mice and explored its possible mechanism.
Qin Xue, Wang Enyang, Gong Tingting, Ma Xiaolin, Ma Qipeng, Gao Song   +5 more
doaj   +1 more source

Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of BRCA Mutant Advanced Ovarian Cancer

Frontiers in Oncology, 2022
Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in ...
Qiang Wei, Dong-Sheng Chen, Yuan-Hua Liu
doaj   +1 more source

Niraparib restrains prostate cancer cell proliferation and metastasis and tumor growth in mice by regulating the lncRNA MEG3/miR-181-5p/GATA6 pathway [PDF]

PeerJ, 2023
Background Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), have gained approval for treating patients with castration-resistant prostate cancer (CRPC). Maternally expressed gene 3 (MEG3), a long non-coding RNA (lncRNA), plays a role in inhibiting
Ji Cheng, Yi Sun, Huacai Zhao, Wei Ren, Dan Gao, Zhigang Wang, Wei Lv, Qingchuan Dong   +7 more
doaj   +2 more sources

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

Therapeutic Advances in Medical Oncology, 2022
Background: The PRIMA phase 3 trial showed niraparib significantly prolongs median progression-free survival (PFS) versus placebo in patients with advanced ovarian cancer (OC) responsive to first-line platinum-based chemotherapy, including those who had ...
Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han, Bhavana Pothuri, Annika Auranen, Dana M. Chase, Domenica Lorusso, Charles Anderson, Sophie Abadie-Lacourtoisie, Noelle Cloven, Elena I. Braicu, Amnon Amit, Andrés Redondo, Ruchit Shah, Nehemiah Kebede, Carol Hawkes, Divya Gupta, Tatia Woodward, David M. O’Malley, Antonio González-Martín   +19 more
doaj   +1 more source

Rapid and temporary improvement of depression and anxiety observed following niraparib administration: a case report

BMC Psychiatry, 2020
Background Cancer patients are disproportionately affected by generalized anxiety and major depression. For many, current treatments for these conditions are ineffective.
Benjamin E. Jewett, Merry N. Miller, Libby A. Ligon, Zachary Carter, Ibrahim Mohammad, Gregory A. Ordway   +5 more
doaj   +1 more source

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

Journal of Translational Medicine, 2021
Background Immune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the ...
Jinyu Meng, Jin Peng, Jie Feng, Jochen Maurer, Xiao Li, Yan Li, Shu Yao, Ran Chu, Xiyu Pan, Junting Li, Ting Zhang, Lu Liu, Qing Zhang, Zeng Yuan, Hualei Bu, Kun Song, Beihua Kong   +16 more
doaj   +1 more source

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China

Frontiers in Pharmacology, 2023
Objective: Niraparib improved survival in platinum-sensitive recurrent ovarian cancer (PSROC) patients versus routine surveillance, accompanied by increased costs.
Yin Shi, Yin Shi, Yin Shi, Di Xiao, Di Xiao, Di Xiao, Shuishi Li, Shuishi Li, Shao Liu, Shao Liu, Shao Liu, Yu Zhang, Yu Zhang   +12 more
doaj   +1 more source

First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis [PDF]

Journal of Immunotherapy and Precision Oncology, 2021
Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV ...
Alistair McLaren, Douglas Cartwright, Ewen Ross, Patricia Roxburgh   +3 more
doaj   +1 more source

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS

Frontiers in Pharmacology, 2022
Background: Several poly ADP ribose polymerase inhibitors (PARPis) are currently approved for the treatment of a variety of cancers. The safety profile of PARPis has not yet been systemically analyzed in the real world.
Xiaojiang Tian, Lin Chen, Di Gai, Sijie He, Xuan Jiang, Ni Zhang   +5 more
doaj   +1 more source

The SP1-SuperEnhancer-SPHK1 Axis Mediates Niraparib Resistance in TNBC

Pharmaceuticals
Background: PARP inhibitors exhibit significant lethality in tumors with BRCA1/2 mutations or homologous recombination defects; however, their clinical application is limited by the rarity of BRCA1/2 mutations, complex resistance mechanisms, and limited ...
Yu-Xia Yuan, Rui-Jia Chen, Gui-Hui Tu, Chao-Qi Li, Long-Long Xu, Yi-Ling Lu, Li-Xian Wu   +6 more
doaj   +1 more source